$2.180
-0.096 (-4.39%)At close
Price Predictions
Open in app to unlock longer-horizon forecasts.
RNAZ Prediction & Forecast by Similar Chart Analysis
Alphio's RNAZ stock price prediction model matches the current Transcode Therapeutics Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $2.13 (-2.18%). The 1-week path is $2.14 (-1.73%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
Should I Buy Transcode Therapeutics Inc Stock?
Transcode Therapeutics Inc (RNAZ) is not a good buy right now due to its extremely low RSI of 6.667, indicating it is oversold, and a staggering year-to-date change of -70.54%, suggesting a significant decline in value. The forward P/E ratio is 0, indicating no expected earnings, and the stock has a current price of 2.18, which is far below its historical SMA of 7.604. The main risk is the negative net income, which reached -19,510,296 in Q1 2026, reflecting ongoing financial struggles.
RNAZ stock price ended at $2.18 on Friday, after losing -4.39%
Transcode Therapeutics Inc (RNAZ) last closed at $2.18, losing -4.39%. These facts feed the 1-day and 1-week RNAZ price prediction above.
Forecast Drivers
Transcode Therapeutics Inc (RNAZ) forecast drivers combine similar chart patterns, seasonality, and moving averages.
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bearish
SMA 200
Bearish
Similar Chart Patterns
Stocks whose recent price path most closely matches RNAZ, ranked by similarity.
Seasonality analysis for RNAZ
Historically the probability of a positive August return for RNAZ is 0.00%. February offers the highest probability of a positive month at 60.34%, while June is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
10-year price projections for RNAZ
| Month | Min Price | Avg Price | Max Price | Potential ROI |
|---|---|---|---|---|
| Aug 2026 | $7.37 | $9.12 | $9.36 | +318.31% |
| Sep 2026 | $11.96 | $12.00 | $12.62 | +450.58% |
| Oct 2026 | $9.13 | $10.52 | $12.41 | +382.69% |
| Nov 2026 | $11.60 | $11.70 | $13.54 | +436.50% |
| Dec 2026 | $10.48 | $12.00 | $12.58 | +450.58% |
In 2026, Transcode Therapeutics Inc (RNAZ) is projected to range from $7.37 to $13.54.
Transcode Therapeutics Inc 2026 monthly forecast
In Aug 2026, Transcode Therapeutics Inc is projected to average $9.12, with a low of $7.37 and high of $9.36.
In Sep 2026, Transcode Therapeutics Inc is projected to average $12.00, with a low of $11.96 and high of $12.62.
In Oct 2026, Transcode Therapeutics Inc is projected to average $10.52, with a low of $9.13 and high of $12.41.
In Nov 2026, Transcode Therapeutics Inc is projected to average $11.70, with a low of $11.60 and high of $13.54.
In Dec 2026, Transcode Therapeutics Inc is projected to average $12.00, with a low of $10.48 and high of $12.58.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.